 AstraZeneca PLC has disclosed Friday that a U.S. Food and Drug Administration advisory committee has voted 13 to 1 not to support approval of roxadustat for the treatment of anaemia in chronic kidney disease CKD in non-dialysis dependent adult patients. Shares of FibroGen Inc. , which was AstraZenecas partner in developing roxadustat, plummeted 34.1 in premarket trading, while AstraZenecas U.S.-listed shares edged up 0.4. 